Enumeral
Enumeral is a biotechnology company focused on the discovery and development of novel antibody therapeutics. The company utilizes a proprietary platform technology to identify and characterize immune modulators, which are critical in the treatment of cancer and other diseases.
History[edit | edit source]
Enumeral was founded in 2009 and is headquartered in Cambridge, Massachusetts. The company was established by a group of scientists and entrepreneurs with expertise in immunology, oncology, and antibody discovery.
Technology[edit | edit source]
Enumeral's platform technology is based on single-cell analysis, which allows for the detailed examination of individual immune cells. This technology enables the identification of unique antibodies that can modulate the immune system, providing potential therapeutic benefits for various diseases.
Single-Cell Analysis[edit | edit source]
The single-cell analysis technology employed by Enumeral involves isolating individual immune cells and analyzing their responses to different stimuli. This approach provides a high-resolution view of the immune system, allowing for the discovery of novel targets and the development of more effective therapies.
Pipeline[edit | edit source]
Enumeral's pipeline includes several antibody candidates in various stages of development. These candidates are designed to target specific immune checkpoints and modulate the immune response to treat cancer and other diseases.
Lead Candidates[edit | edit source]
- ENUM-001: An antibody targeting PD-1, a checkpoint protein on immune cells that, when inhibited, can enhance the body's immune response against cancer cells.
- ENUM-002: An antibody targeting CTLA-4, another checkpoint protein that plays a critical role in regulating immune responses.
Collaborations[edit | edit source]
Enumeral has established collaborations with various academic institutions and pharmaceutical companies to advance its research and development efforts. These partnerships are aimed at leveraging complementary expertise and resources to accelerate the discovery and development of new therapies.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This biotechnology article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
